Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 47
Filter
Add more filters










Publication year range
1.
EJNMMI Res ; 6(1): 3, 2016 Dec.
Article in English | MEDLINE | ID: mdl-26769345

ABSTRACT

BACKGROUND: As model system, a solid-tumor patient-derived xenograft (PDX) model characterized by high peptide receptor expression and histological tissue homogeneity was used to study radiopeptide targeting. In this solid-tumor model, high tumor uptake of targeting peptides was expected. However, in vivo SPECT images showed substantial heterogeneous radioactivity accumulation despite homogenous receptor distribution in the tumor xenografts as assessed by in vitro autoradiography. We hypothesized that delivery of peptide to the tumor cells is dictated by adequate local tumor perfusion. To study this relationship, sequential SPECT/CT and MRI were performed to assess the role of vascular functionality in radiopeptide accumulation. METHODS: High-resolution SPECT and dynamic contrast-enhanced (DCE)-MRI were acquired in six mice bearing PC295 PDX tumors expressing the gastrin-releasing peptide (GRP) receptor. Two hours prior to SPECT imaging, animals received 25 MBq (111)In(DOTA-(ßAla)2-JMV594) (25 pmol). Images were acquired using multipinhole SPECT/CT. Directly after SPECT imaging, MR images were acquired on a 7.0-T dedicated animal scanner. DCE-MR images were quantified using semi-quantitative and quantitative models. The DCE-MR and SPECT images were spatially aligned to compute the correlations between radioactivity and DCE-MRI-derived parameters over the tumor. RESULTS: Whereas histology, in vitro autoradiography, and multiple-weighted MRI scans all showed homogenous tissue characteristics, both SPECT and DCE-MRI showed heterogeneous distribution patterns throughout the tumor. The average Spearman's correlation coefficient between SPECT and DCE-MRI ranged from 0.57 to 0.63 for the "exchange-related" DCE-MRI perfusion parameters. CONCLUSIONS: A positive correlation was shown between exchange-related DCE-MRI perfusion parameters and the amount of radioactivity accumulated as measured by SPECT, demonstrating that vascular function was an important aspect of radiopeptide distribution in solid tumors. The combined use of SPECT and MRI added crucial information on the perfusion efficiency versus radiopeptide uptake in solid tumors and showed that functional tumor characteristics varied locally even when the tissue appeared homogenous on current standard assessment techniques.

2.
Mol Cell Endocrinol ; 393(1-2): 120-8, 2014 Aug 05.
Article in English | MEDLINE | ID: mdl-24953973

ABSTRACT

The only peripherally released orexigenic hormone, ghrelin, plays a key role in food intake and body weight regulation. Antagonizing the ghrelin receptor, GHS-R1a, represents a promising approach for anti-obesity therapy. In our study, two novel GHS-R1a antagonists JMV4208 and JMV3002, which are trisubstituted 1,2,4-triazoles, decreased food intake in fasted lean mice in a dose-dependent manner, with ED50 values of 5.25 and 2.05 mg/kg, respectively. Both compounds were stable in mouse blood, with half-lives of 90 min (JMV4208) and 60 min (JMV3002), and disappeared from the blood 8h after administration. Fourteen days of treatment with the ghrelin antagonists (20 mg/kg twice a day) decreased food intake, body weight and adipose tissue mass in mice with diet-induced obesity (DIO). These results are likely attributable to an impact on food intake reduction and an attenuated expression of the lipogenesis-promoting enzymes (acetyl-CoA carboxylase 1 in subcutaneous fat and fatty acid synthase in subcutaneous and intraperitoneal fat). The decrease in fat mass negatively impacted circulating leptin levels. These data suggest that JMV4208 and JMV3002 could be useful therapeutic agents for the treatment of obesity.


Subject(s)
Adipose Tissue/drug effects , Body Weight/drug effects , Eating/drug effects , Picolinic Acids/pharmacology , Receptors, Ghrelin/antagonists & inhibitors , Triazoles/pharmacology , Animals , Dose-Response Relationship, Drug , Mice , Mice, Inbred C57BL , Picolinic Acids/chemistry , Triazoles/chemistry
3.
Physiol Res ; 62(4): 435-44, 2013.
Article in English | MEDLINE | ID: mdl-23590608

ABSTRACT

Ghrelin and agonists of its receptor GHS-R1a are potential substances for the treatment of cachexia. In the present study, we investigated the acute and long term effects of the GHS R1a agonist JMV 1843 (H Aib-DTrp-D-gTrp-CHO) on food intake, body weight and metabolic parameters in lean C57BL/6 male mice. Additionally, we examined stability of JMV 1843 in mouse blood serum. A single subcutaneous injection of JMV 1843 (0.01-10 mg/kg) increased food intake in fed mice in a dose-dependent manner, up to 5-times relative to the saline-treated group (ED(50)=1.94 mg/kg at 250 min). JMV 1843 was stable in mouse serum in vitro for 24 h, but was mostly eliminated from mouse blood after 2 h in vivo. Ten days of treatment with JMV 1843 (subcutaneous administration, 10 or 20 mg/kg/day) significantly increased food intake, body weight and mRNA expression of the orexigenic neuropeptide Y and agouti-related peptide in the medial basal hypothalamus and decreased the expression of uncoupling protein 1 in brown adipose tissue. Our data suggest that JMV 1843 could have possible future uses in the treatment of cachexia.


Subject(s)
Agouti-Related Protein/metabolism , Appetite Stimulants/pharmacology , Eating/drug effects , Ghrelin/agonists , Hypothalamus/drug effects , Neuropeptide Y/metabolism , Oligopeptides/pharmacology , Weight Gain/drug effects , Adipose Tissue, Brown/drug effects , Adipose Tissue, Brown/metabolism , Agouti-Related Protein/genetics , Animals , Appetite Stimulants/administration & dosage , Appetite Stimulants/pharmacokinetics , Dose-Response Relationship, Drug , Ghrelin/metabolism , Hypothalamus/metabolism , Indoles , Injections, Subcutaneous , Ion Channels/metabolism , Male , Mice , Mice, Inbred C57BL , Mitochondrial Proteins/metabolism , Neuropeptide Y/genetics , Oligopeptides/administration & dosage , Oligopeptides/pharmacokinetics , RNA, Messenger/metabolism , Receptors, Ghrelin/agonists , Receptors, Ghrelin/metabolism , Signal Transduction/drug effects , Tryptophan/analogs & derivatives , Uncoupling Protein 1 , Up-Regulation
4.
Biochim Biophys Acta ; 1828(2): 455-60, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23122777

ABSTRACT

Recently, we demonstrated that TLQP-21 triggers lipolysis and induces resistance to obesity by reducing fat accumulation [1]. TLQP-21 is a 21 amino acid peptide cleavage product of the neuroprotein VGF and was first identified in rat brain. Although TLQP-21 biological activity and its molecular signaling is under active investigation, a receptor for TLQP-21 has not yet been characterized. We now demonstrate that TLQP-21 stimulates intracellular calcium mobilization in CHO cells. Furthermore, using Atomic Force Microscopy (AFM), we also provide evidence of TLQP-21 binding-site characteristics in CHO cells. AFM was used in force mapping mode equipped with a cantilever suitably functionalized with TLQP-21. Attraction of this functionalized probe to the cell surface was specific and consistent with the biological activity of TLQP-21; by contrast, there was no attraction of a probe functionalized with biologically inactive analogues. We detected interaction of the peptide with the binding-site by scanning the cell surface with the cantilever tip. The attractive force between TLQP-21 and its binding site was measured, statistically analyzed and quantified at approximately 40 pN on average, indicating a single class of binding sites. Furthermore we observed that the distribution of these binding sites on the surface was relatively uniform.


Subject(s)
Biophysics/methods , Obesity/metabolism , Peptide Fragments/chemistry , Peptides/chemistry , Animals , Binding Sites , CHO Cells , Calcium/metabolism , Cell Adhesion , Cell Membrane/metabolism , Cricetinae , Hypothalamus/metabolism , Ligands , Mice , Microscopy, Atomic Force/methods , Microscopy, Phase-Contrast/methods , Models, Biological , Models, Statistical , Rats , Time Factors
5.
Neurochem Int ; 59(6): 889-95, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21843570

ABSTRACT

Many peripheral substances, including ghrelin, induce neuronal activation in the brain. In the present study, we compared the effect of subcutaneously administered ghrelin and its three stable agonists: Dpr(3)ghr ([Dpr(N-octanoyl)(3)] ghrelin) (Dpr - diaminopropionic acid), YA GHRP-6 (H-Tyr-Ala-His-DTrp-Ala-Trp-DPhe-Lys-NH(2)), and JMV1843 (H-Aib-DTrp-D-gTrp-CHO) on the Fos expression in food intake-responsive brain areas such as the hypothalamic paraventricular (PVN) and arcuate (ARC) nuclei, the nucleus of the solitary tract (NTS), and area postrema (AP) in male C57BL/6 mice. Immunohistochemical analysis showed that acute subcutaneous dose of each substance (5mg/kg b.w.), which induced a significant food intake increase, elevated Fos protein expression in all brain areas studied. Likewise ghrelin, each agonist tested induced distinct Fos expression overall the PVN. In the ARC, ghrelin and its agonists specifically activated similarly distributed neurons. Fos occurrence extended from the anterior (aARC) to middle (mARC) ARC region. In the latter part of the ARC, the Fos profiles were localized bilaterally, especially in the ventromedial portions of the nucleus. In the NTS, all substances tested also significantly increased the number of Fos profiles in neurons, which also revealed specific location, i.e., in the NTS dorsomedial subnucleus (dmNTS) and the area subpostrema (AsP). In addition, cells located nearby the NTS, in the AP, also revealed a significant increase in number of Fos-activated cells. These results demonstrate for the first time that ghrelin agonists, regardless of their different chemical nature, have a significant and similar activating impact on specific groups of neurons that can be a part of the circuits involved in the food intake regulation. Therefore there is a real potency for ghrelin agonists to treat cachexia and food intake disorders. Thus, likewise JMV1843, the other ghrelin agonists represent substances that might be involved in trials for clinical purposes.


Subject(s)
Appetite Regulation/drug effects , Appetite Regulation/physiology , Brain Chemistry/drug effects , Ghrelin/agonists , Ghrelin/physiology , Neurons/drug effects , Proto-Oncogene Proteins c-fos/biosynthesis , Up-Regulation/drug effects , Animals , Biomarkers/metabolism , Brain Chemistry/physiology , Feeding and Eating Disorders/drug therapy , Feeding and Eating Disorders/physiopathology , Ghrelin/analogs & derivatives , Male , Mice , Mice, Inbred C57BL , Neurons/physiology , Up-Regulation/physiology
6.
J Neuroendocrinol ; 21(9): 777-85, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19703102

ABSTRACT

In the present study, we explore the central nervous system mechanism underlying the chronic central effects of ghrelin with respect to increasing body weight and body fat. Specifically, using a recently developed ghrelin receptor antagonist, GHS-R1A (JMV2959), we investigate the role of GHS-R1A in mediating the effects of ghrelin on energy balance and on hypothalamic gene expression. As expected, in adult male rats, chronic central treatment with ghrelin for 14 days, when compared to vehicle-treated control rats, resulted in an increased body weight, lean mass and fat mass (assessed by dual X-ray absorptiometry), dissected white fat pad weight, cumulative food intake, food efficiency, respiratory exchange ratio and a decrease of energy expenditure. Co-administration of the ghrelin receptor antagonist JMV2959 suppressed/blocked the majority of these effects, with the notable exception of ghrelin-induced food intake and food efficiency. The hypothesis emerging from these data, namely that GHS-R1A mediates the chronic effects of ghrelin on fat accumulation, at least partly independent of food intake, is discussed in light of the accompanying data regarding the hypothalamic genes coding for peptides and receptors involved in energy balance regulation, which were found to have altered expression in these studies.


Subject(s)
Central Nervous System/drug effects , Ghrelin/pharmacology , Hormone Antagonists/pharmacology , Obesity/chemically induced , Receptors, Ghrelin/antagonists & inhibitors , Animals , Body Composition/drug effects , Body Weight/drug effects , Central Nervous System/metabolism , Central Nervous System/physiology , Eating/drug effects , Gene Expression/drug effects , Ghrelin/administration & dosage , Ghrelin/adverse effects , Ghrelin/antagonists & inhibitors , Hormones/blood , Hypothalamus/drug effects , Hypothalamus/metabolism , Injections, Intraventricular , Male , Obesity/blood , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effects
7.
Eat Weight Disord ; 13(3): e67-74, 2008 Sep.
Article in English | MEDLINE | ID: mdl-19011367

ABSTRACT

Energy homeostasis is controlled by a complex regulatory system of molecules that affect food intake and that are critical for maintaining a stable body weight during life. Ghrelin is a peptide of 28 amino acid synthesized predominantly by the stomach and the gut, which activate the type 1a growth hormone (GH) secretagogue receptor (GHS-R1a), a G-protein coupled receptor. The acylated form of ghrelin potently stimulates GH secretion both in vitro and in vivo in several animal species, including humans. Beside the endocrine effect, ghrelin shows also extraendocrine activities, including stimulation of feeding behaviour. Several classes of small synthetic peptide and non-peptide ligands of the GHS-R1a have been described and are able to release GH and stimulate food intake. However, in time, it appeared that the stimulating effects on GH secretion could be divorced from those on food intake, suggesting that more than a single receptor might be involved. Several experimental data have even questioned the physiological role of ghrelin in the control of GH secretion and energy metabolism. By using novel agonists, partial agonists, and antagonists for the GHS-R1a receptor, we have studied whether the stimulation of this receptor could account for the purported physiological role of ghrelin. Our results demonstrate that the ability to bind in vitro the GHS-R1a is not predictive of the in vivo biological activity of the compounds and that the endocrine and extraendocrine effects could be mediated also by receptors different from the GHS-R1a.


Subject(s)
Feeding Behavior/physiology , Ghrelin/physiology , Growth Hormone/metabolism , Human Growth Hormone/metabolism , Receptors, Ghrelin/physiology , Triazoles/adverse effects , Analysis of Variance , Animals , Energy Metabolism , Ghrelin/metabolism , Homeostasis , Humans , Rats , Rats, Sprague-Dawley , Receptors, G-Protein-Coupled/antagonists & inhibitors , Receptors, G-Protein-Coupled/metabolism , Signal Transduction/physiology , Triazoles/administration & dosage
8.
J Muscle Res Cell Motil ; 24(7): 387-97, 2003.
Article in English | MEDLINE | ID: mdl-14677641

ABSTRACT

Beta-dystroglycan is expressed in a wide variety of tissues and has generally been reported with an Mr of 43 kDa, sometimes accompanied with a 31 kDa protein assumed to be a truncated product. This molecule was recently identified as the anomalous beta-dystroglycan expressed in various carcinoma cell lines. We produced and characterized a G5 polyclonal antibody specific to beta-dystroglycan that is directed against the C-terminal portion of the molecule. We provide evidence that beta-dystroglycan may vary in size and properties by studying different Xenopus tissues. Besides normal beta-dystroglycan with an Mr of 43 kDa in smooth and cardiac muscle and sciatic nerve extracts, we found it in skeletal muscle and brain proteins with an Mr of 38 and 65 kDa, respectively. Glycosylation properties and proteolytic susceptibilities of these different beta-dystroglycans are analysed and compared in this work. Crosslinking experiments with various beta-dystroglycan preparations obtained from skeletal and cardiac muscles and brain gave rise to specific new covalent products with Mr of 125 kDa (doublet band), or 120 and 130 kDa, or 140 and 240 kDa, respectively. We provide evidence, using various similar beta-dystroglycan preparations, that the immunoprecipitation procedure with G5 specific polyclonal antibody allows consistent pelleting of various dystrophin-family isoforms. Skeletal muscles from Xenopus reveals the presence of two distinct beta-dystroglycan complexes, one with dystrophin and another one which involves alpha-dystrobrevin. Cardiac muscle and brain from Xenopus are shown to contain three beta-dystroglycan complexes related to various dystrophin-family isoforms. Dystrophin or alpha-dystrobrevin or Dp71 were found in cardiac muscle and dystrophin or Dp180 or Up71 in brain. This variability in the relationship between beta-dystroglycan and dystrophin-family isoforms suggests that each protein--currently known as dystrophin associated protein--could not be present in each of these complexes.


Subject(s)
Cytoskeletal Proteins/metabolism , Dystrophin-Associated Proteins , Dystrophin/metabolism , Membrane Glycoproteins/metabolism , Membrane Proteins/metabolism , Muscle, Skeletal/metabolism , Muscle, Smooth/metabolism , Animals , Brain/metabolism , Dystroglycans , Glycosylation , Mice , Myocardium/metabolism , Protein Binding , Protein Isoforms/metabolism , Sciatic Nerve/metabolism , Xenopus laevis
9.
Eur J Histochem ; 47(1): 29-38, 2003.
Article in English | MEDLINE | ID: mdl-12685555

ABSTRACT

Since all organs (i.e. skeletal, cardiac, smooth muscles and sciatic nerve) are never only taken from a single patient, all these tissues were obtained from one cynomolgus monkey, a model closely resembling humans. This work describes an up-to-date reinvestigation of the dystrophin-glycoprotein complex and related molecules in various monkey tissues such those cited above. We used monoclonal and polyclonal antibodies produced in our laboratory, which are directed against dystrophin, utrophin, short-dystrophin products, alpha-dystrobrevin, beta-dystroglycan, alpha-syntrophin, alpha-, beta-, gamma-, delta-, epsilon-sarcoglycan, and sarcospan. For each molecule, we determined their molecular weight and tissue localization. Regardless of the tissue analyzed, at least one dystrophin or utrophin as full-length molecule and one short-dystrophin product or dystrobrevin as proteins belonging to the dystrophin superfamily were found. Beta-dystroglycan, beta and delta sarcoglycans were always detected, while other sarcoglycans varied from all to only three components. Epsilon sarcoglycan appears to be specific to smooth muscle, which is devoid of alpha sarcoglycan. Sarcospan is only absent from sciatic nerve structures. Among the different muscles investigated in this study, short dystrophin products are only present in cardiac muscle. All of these findings are summarized in one table, which highlight in one single animal the variability of the dystrophin-glycoprotein complex components in relation with the organ studied. This statement is important because any attempt to estimate protein restoration needs in each study the knowledge of the expected components that should be considered normal.


Subject(s)
Cytoskeletal Proteins/metabolism , Dystrophin/metabolism , Macaca fascicularis , Membrane Proteins/metabolism , Muscles/metabolism , Sciatic Nerve/metabolism , Animals , Blotting, Western , Cytoskeletal Proteins/immunology , Dystrophin/immunology , Fluorescent Antibody Technique, Direct , Membrane Proteins/immunology , Microscopy, Fluorescence , Muscles/cytology , Sciatic Nerve/cytology , Tissue Distribution , Utrophin
10.
J Endocrinol Invest ; 25(8): RC26-8, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12240910

ABSTRACT

EP1572 UMV1843 [Aib-DTrp-DgTrp-CHO]) is a new peptido-mimetic GH secretagogue (GHS) showing binding potency to the GHS-receptor in animal and human tissues similar to that of ghrelin and peptidyl GHS. EP1572 induces marked GH increase after s.c. administration in neonatal rats. Preliminary data in 2 normal young men show that: 1) acute i.v. EP1572 administration (1.0 microg/kg) induces strong and selective increase of GH levels; 2) single oral EP1572 administration strongly and reproducibly increases GH levels even after a dose as low as 0.06 mg/kg. Thus, EP1572 is a new peptido-mimetic GHS with potent and selective GH-releasing activity.


Subject(s)
Growth Hormone/metabolism , Oligopeptides/pharmacokinetics , Adult , Animals , Binding, Competitive , Dose-Response Relationship, Drug , Ghrelin , Growth Hormone/blood , Human Growth Hormone/blood , Human Growth Hormone/metabolism , Humans , Indoles , Male , Oligopeptides/administration & dosage , Oligopeptides/metabolism , Peptide Hormones/metabolism , Pituitary Gland/metabolism , Rats , Tryptophan/analogs & derivatives
11.
J Org Chem ; 66(20): 6541-4, 2001 Oct 05.
Article in English | MEDLINE | ID: mdl-11578202

ABSTRACT

A general method has been developed for the synthesis of N-tert-butyloxycarbonyl N-carboxyanhydrides from beta-amino acids using Vilsmeier complex. These beta-UNCA are stable, and the reactivity with different nucleophiles (alcohol, amine, lithium enolate) was studied.

12.
J Histochem Cytochem ; 49(7): 857-65, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11410610

ABSTRACT

We present an up-to-date study on the nature, at the protein level, of various members of the dystrophin complex at the muscle cell membrane by comparing red and white caudal muscles from Torpedo marmorata. Our investigations involved immunodetection approaches and Western blotting analysis. We determined the presence or absence of different molecules belonging to the dystrophin family complex by analyzing their localization and molecular weight. Specific antibodies directed against dystrophin, i.e., DRP2 alpha-dystrobrevin, beta-dystroglycan, alpha-syntrophin, alpha-, beta-, gamma-, and delta-sarcoglycan, and sarcospan, were used. The immunofluorescence study (confocal microscopy) showed differences in positive immunoreactions at the sarcolemmal membrane in these slow-type and fast-type skeletal muscle fibers. Protein extracts from T. marmorata red and white muscles were analyzed by Western blotting and confirmed the presence of dystrophin and associated proteins at the expected molecular weights. Differences were confirmed by comparative immunoprecipitation analysis of enriched membrane preparations with anti-beta-dystroglycan polyclonal antibody. These experiments revealed clear complex or non-complex formation between members of the dystrophin system, depending on the muscle type analyzed. Differences in the potential function of these various dystrophin complexes in fast or slow muscle fibers are discussed in relation to previous data obtained in corresponding mammalian tissues. (J Histochem Cytochem 49:857-865, 2001)


Subject(s)
Dystrophin-Associated Proteins , Dystrophin/metabolism , Muscle Fibers, Fast-Twitch/metabolism , Animals , Blotting, Western , Calcium-Binding Proteins , Cytoskeletal Proteins/metabolism , Dystroglycans , Membrane Glycoproteins/metabolism , Membrane Proteins/metabolism , Microscopy, Confocal , Microscopy, Fluorescence , Muscle Proteins/metabolism , Precipitin Tests , Sarcoglycans , Torpedo
13.
Biopolymers ; 55(2): 165-86, 2000.
Article in English | MEDLINE | ID: mdl-11074412

ABSTRACT

The functionalization of peptides and proteins by aldehyde or keto groups has become the subject of intensive research since the discovery of the inhibition properties of peptide aldehydes and the advent of protein engineering. The first part of this review focuses upon the tremendous efforts devoted to the solid-phase synthesis of peptide aldehydes as protease inhibitors. The second part describes the utility of the aldehyde or keto functionalities for the site-specific modification of peptides or proteins.


Subject(s)
Peptides/chemical synthesis , Proteins/chemical synthesis , Aldehydes/chemistry , Formic Acid Esters , Ketones/chemistry , Resins, Plant
14.
Eur J Pharmacol ; 403(1-2): 17-25, 2000 Sep 01.
Article in English | MEDLINE | ID: mdl-10969139

ABSTRACT

alpha-amidation of a peptide (which takes place from a glycine-extended precursor) is required to produce biologically active amidated hormones, such as gastrin-releasing peptide (GRP)/Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH(2) (bombesin). It was shown that glycine-extended gastrin mediates mitogenic effects on various cell lines by interacting with a specific receptor, different from the classical CCK(1) or CCK(2) receptors. On the basis of this observation, we have extended the concept of obtaining active glycine-extended forms of others amidated peptides to produce new active analogues. In this study, we have tested the biological behaviour of a synthetic analogue of the glycine-extended bombesin (para-hydroxy-phenyl-propionyl-Gln-Trp-Ala-Val-Gly-His-Leu-Met-Gly-OH or JMV-1458) on various in vitro models. We showed that compound JMV-1458 was able to inhibit specific (3-[125I]iodotyrosyl(15)) GRP ([125I]GRP) binding in rat pancreatic acini and in Swiss 3T3 cells with K(i) values of approximately 10(-8) M. In isolated rat pancreatic acini, we found that JMV-1458 induced inositol phosphates production and amylase secretion in a dose-dependent manner. In Swiss 3T3 cells, the glycine-extended bombesin analogue dose-dependently produced [3H]thymidine incorporation. By using potent GRP/bombesin receptor antagonists, we showed that this synthetic glycine-extended bombesin analogue induces its biological activities via the classical GRP/bombesin receptor.


Subject(s)
Bombesin/analogs & derivatives , Bombesin/metabolism , Receptors, Bombesin/metabolism , 3T3 Cells , Amylases/drug effects , Amylases/metabolism , Animals , Binding, Competitive/drug effects , Bombesin/chemistry , Bombesin/pharmacology , Cell Division/drug effects , Dose-Response Relationship, Drug , Inositol Phosphates/metabolism , Iodine Radioisotopes , Male , Mice , Pancreas/cytology , Pancreas/metabolism , Rats , Rats, Wistar
15.
J Med Chem ; 43(12): 2356-61, 2000 Jun 15.
Article in English | MEDLINE | ID: mdl-10882361

ABSTRACT

Analogues of bombesin which incorporate dipeptide or turn mimetics have been synthesized. One of them (compound 11) containing a seven-membered lactam ring revealed a good affinity for GRP/BN receptors on rat pancreatic acini (K(i) value of 1.7 +/- 0.4 nM) and on Swiss 3T3 cells (K(i) value of 1.0 +/- 0.2 nM). On the basis of this observation, antagonists containing the same dipeptide mimic were obtained by modification of the C-terminal part of the bombesin analogues. The most potent constrained compounds (15 and 17) were able to antagonize 1 nM bombesin-stimulated amylase secretion from rat pancreatic acini with high potency (K(i) = 21 +/- 3 and 3.3 +/- 1.0 nM, respectively) and 10(-7) M bombesin-stimulated ¿(3)Hthymidine incorporation into Swiss 3T3 cells (K(i) = 7.8 +/- 2. 0 and 0.5 +/- 0.1 nM, respectively).


Subject(s)
Bombesin/analogs & derivatives , Bombesin/chemical synthesis , Oligopeptides/chemical synthesis , Receptors, Bombesin/agonists , Receptors, Bombesin/antagonists & inhibitors , 3T3 Cells , Amylases/metabolism , Animals , Bombesin/chemistry , Bombesin/pharmacology , In Vitro Techniques , Male , Mice , Molecular Mimicry , Oligopeptides/chemistry , Oligopeptides/metabolism , Oligopeptides/pharmacology , Pancreas/drug effects , Pancreas/metabolism , Rats , Rats, Wistar , Receptors, Bombesin/metabolism , Structure-Activity Relationship , Thymidine/metabolism
16.
Protein Sci ; 8(11): 2347-54, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10595537

ABSTRACT

The knowledge of the binding sites of G protein-coupled cholecystokinin receptors represents important insights that may serve to understand their activation processes and to design or optimize ligands. Our aim was to identify the amino acid of the cholecystokinin-A receptor (CCK-AR) binding site in an interaction with the sulfate of CCK, which is crucial for CCK binding and activity. A three-dimensional model of the [CCK-AR-CCK] complex was built. In this model, Arg197 was the best candidate residue for a ionic interaction with the sulfate of CCK. Arg197 was exchanged for a methionine by site-directed mutagenesis. Wild-type and mutated CCK-AR were transiently expressed in COS-7 cells for pharmacological and functional analysis. The mutated receptor on Arg197 did not bind the agonist radioligand 125I-BH-[Thr, Nle]-CCK-9; however, it bound the nonpeptide antagonist [3H]-SR27,897 as the wild-type receptor. The mutant was approximately 1,470- and 3,200-fold less potent than the wild-type CCK-AR to activate G proteins and to induce inositol phosphate production, respectively. This is consistent with the 500-fold lower potency and 800-fold lower affinity of nonsulfated CCK relative to sulfated CCK on the wild-type receptor. These data, together with those showing that the mutated receptor failed to discriminate nonsulfated and sulfated CCK while it retained other pharmacological features of the CCK-AR, strongly support an interaction between Arg197 of the CCK-AR binding site and the sulfate of CCK. In addition, the mutated CCK-AR resembled the low affinity state of the wild-type CCK-AR, suggesting that Arg197-sulfate interaction regulates conformational changes of the CCK-AR that are required for its physiological activation.


Subject(s)
Arginine , Cholecystokinin/chemistry , Cholecystokinin/metabolism , Receptors, Cholecystokinin/chemistry , Receptors, Cholecystokinin/metabolism , Amino Acid Sequence , Amino Acid Substitution , Animals , Binding Sites , COS Cells , Computer Simulation , Humans , Indoleacetic Acids/pharmacokinetics , Inositol Phosphates/metabolism , Iodine Radioisotopes , Kinetics , Models, Molecular , Mutagenesis, Site-Directed , Protein Conformation , Radioligand Assay , Receptor, Cholecystokinin A , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Thiazoles/pharmacokinetics , Transfection , Tritium
17.
Histochem J ; 31(7): 425-32, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10475570

ABSTRACT

Abnormal dystrophin expression is directly responsible for Duchenne and Becker muscular dystrophies. In skeletal muscle, dystrophin provides a link between the actin network and the extracellular matrix via the dystrophin-associated protein complex. In mature skeletal muscle, utrophin is a dystrophin-related protein localized mainly at the neuromuscular junction, with the same properties as dystrophin in terms of linking the protein complex. Utrophin could potentially overcome the absence of dystrophin in dystrophic skeletal muscles. In cardiac muscle, dystrophin and utrophin were both found to be present with a distinct subcellular distribution in Purkinje fibres, i.e. utrophin was limited to the cytoplasm, while dystrophin was located in the cytoplasmic membrane. In this study, we used this particular characteristic of cardiac Purkinje fibres and demonstrated that associated proteins of dystrophin and utrophin are different in this structure. We conclude, contrary to skeletal muscle, dystrophin-associated proteins do not form a complex in Purkinje fibres. In addition, we have indirect evidence of the presence of two different 400 kDa dystrophins in Purkinje fibres.


Subject(s)
Cytoskeletal Proteins/metabolism , Dystrophin-Associated Proteins , Dystrophin/metabolism , Membrane Proteins/metabolism , Purkinje Fibers/metabolism , Animals , Blotting, Western , Cattle , Dystroglycans , Membrane Glycoproteins/metabolism , Muscle Proteins/metabolism , Organ Specificity , Sarcoglycans , Utrophin
18.
J Biol Chem ; 274(33): 23191-7, 1999 Aug 13.
Article in English | MEDLINE | ID: mdl-10438490

ABSTRACT

Recently, we reported that the mutation of His(207) to Phe located in the second extracellular loop of the cholecystokinin B receptor strongly affected cholecystokinin (CCK) binding (Silvente-Poirot, S., Escrieut, C., and Wank, S. A. (1998) Mol. Pharmacol. 54, 364-371). To characterize the functional group in CCK that interacts with His(207), we first substituted His(207) to Ala. This mutation decreased the affinity and the potency of CCK to produce total inositol phosphates 302-fold and 456-fold without affecting the expression of the mutant receptor. The screening of L-alanine-modified CCK peptides to bind and activate the wild type and mutant receptors allowed the identification of the interaction of the C-terminal Asp(8) of CCK with His(207). The H207A-CCKBR mutant, unlike the wild type receptor, was insensitive to substitution of Asp(8) of CCK to other amino acid residues. This interaction was further confirmed by mutating His(207) to Asp. The affinity of CCK for the H207D-CCKBR mutant was 100-fold lower than for the H207A-CCKBR mutant, consistent with an electrostatic repulsion between the negative charges of the two interacting aspartic acids. Peptides with neutral amino acids in position eight of CCK reversed this effect and displayed a gain of affinity for the H207D mutant compared with CCK. To date, this is the first report concerning the identification of a direct contact point between the CCKB receptor and CCK.


Subject(s)
Aspartic Acid/metabolism , Cholecystokinin/metabolism , Histidine/metabolism , Receptors, Cholecystokinin/metabolism , Amino Acid Sequence , Animals , Binding Sites , COS Cells , Cholecystokinin/chemistry , Mutagenesis, Site-Directed , Receptor, Cholecystokinin B , Receptors, Cholecystokinin/chemistry , Receptors, Cholecystokinin/genetics , Structure-Activity Relationship
19.
J Biol Chem ; 274(29): 20457-64, 1999 Jul 16.
Article in English | MEDLINE | ID: mdl-10400673

ABSTRACT

The cholecystokinin-A receptor (CCK-AR) is a G protein-coupled receptor that mediates important central and peripheral cholecystokinin actions. Residues of the CCK-AR binding site that interact with the C-terminal part of CCK that is endowed with biological activity are still unknown. Here we report on the identification of Arg-336 and Asn-333 of CCK-AR, which interact with the Asp-8 carboxylate and the C-terminal amide of CCK-9, respectively. Identification of the two amino acids was achieved by dynamics-based docking of CCK in a refined three-dimensional model of CCK-AR using, as constraints, previous results that demonstrated that Trp-39/Gln-40 and Met-195/Arg-197 interact with the N terminus and the sulfated tyrosine of CCK, respectively. Arg-336-Asp-8 and Asn-333-amide interactions were pharmacologically assessed by mutational exchange of Arg-336 and Asn-333 in the receptor or reciprocal elimination of the partner chemical functions in CCK. This study also allowed us to demonstrate that (i) the identified interactions are crucial for stabilizing the high affinity phospholipase C-coupled state of the CCK-AR.CCK complex, (ii) Arg-336 and Asn-333 are directly involved in interactions with nonpeptide antagonists SR-27,897 and L-364,718, and (iii) Arg-336 but not Asn-333 is directly involved in the binding of the peptide antagonist JMV 179 and the peptide partial agonist JMV 180. These data will be used to obtain an integrated dynamic view of the molecular processes that link agonist binding to receptor activation.


Subject(s)
Arginine/metabolism , Asparagine/metabolism , Aspartic Acid/metabolism , Cholecystokinin/metabolism , Receptors, Cholecystokinin/metabolism , Amides/metabolism , Animals , Binding Sites , COS Cells , Cholecystokinin/chemistry , Computer Simulation , Humans , Models, Molecular , Mutagenesis, Site-Directed , Protein Conformation , Receptor, Cholecystokinin A , Receptors, Cholecystokinin/chemistry , Receptors, Cholecystokinin/genetics , Type C Phospholipases/metabolism
20.
Amino Acids ; 16(3-4): 345-79, 1999.
Article in English | MEDLINE | ID: mdl-10399020

ABSTRACT

Some of the chemistry of amino acids going on in our laboratory (Laboratoire des Amino acides Peptides et Protéines) is described as well as some mass spectrometry methodology for their characterization particularly on solid supports. Several aspects are presented including: (i) the stereoselective synthesis of natural and unnatural amino acids using 2-hydroxypinan-3-one as chiral auxiliary; (ii) the stereoselective synthesis of natural and unnatural amino acids by deracemization of alpha-amino acids via their ketene derivatives; (iii) the synthesis of alpha-aryl-alpha-amino acids via reaction of organometallics with a glycine cation; (iv) the diastereoselective synthesis of glycosyl-alpha-amino acids; (v) the synthesis of beta-amino acids using alpha-aminopyrrolidinopiperazinediones as chiral templates; (vi) the reactivity of urethane-N-protected N-carboxyanhydrides. To characterize natural and non natural amino acids through their immonium ions by mass spectrometry, some methodology is also described.


Subject(s)
Amino Acids/chemistry , Glycopeptides/chemical synthesis , Glycopeptides/chemistry , Laboratories , Peptide Biosynthesis , Peptides/chemistry , Proteins/chemistry , Schiff Bases/chemistry , Stereoisomerism
SELECTION OF CITATIONS
SEARCH DETAIL
...